An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC

Inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR) using small-molecule tyrosine kinase inhibitors (TKIs) or monoclonal antibodies is often ineffective in treating cancers harboring wild-type EGFR. Given the fact that EGFR possesses a kinase-independent pro-survival f...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yanping, Cuan, Xiangdan, Zhu, Weiwei, Yang, Xingying, Zhao, Yunli, Sheng, Jun, Zi, Chengting, Wang, Xuanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531337/
https://www.ncbi.nlm.nih.gov/pubmed/37762316
http://dx.doi.org/10.3390/ijms241814012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531337/
https://www.ncbi.nlm.nih.gov/pubmed/37762316
http://dx.doi.org/10.3390/ijms241814012

Ejemplares similares